tirzepatide surpass New research from the SURPASS-EARLY trial found that improved glycemic control, body weight, and waist circumference over 104 weeks compared with intensified conventional care in adults with early type 2 diabetes SURPASS-CVOT: Tirzepatide better than dulagluti...

Reactive management at this tier is consistently slower than prophylaxis

These benefits can also reduce the risk of cardiovascular events in people living with obesity or diabetes

Gut Health & Inflammation Testing Advanced microbiome and inflammation panels reveal underlying causes of bloating, fatigue, or slow metabolism so we can target the root, not just the symptom

Neurotoxic microglia promote TDP-43 proteinopathy in progranulin deficiency

Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist with similar effects

This quest for optimal health often leads to a desire to integrate different approaches, sparking questions about how they might work together